U.S. stock market midday update: Dare Bioscience down 15.90%, trading volume increased, market sentiment fluctuations attract attention

U.S. Stock Market Midday Update Dare Bioscience, down 15.90%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Novo Nordisk up 2.69%. Based on recent key news: On May 6, Novo Nordisk announced its Q1 2026 results, with revenue increasing by 24% year-on-year to DKK 96.82 billion, exceeding expectations. Although earnings were below expectations, strong demand for GLP-1 drugs led the company to raise its full-year outlook, driving the stock price up. On May 6, Novo Nordisk raised its 2026 performance expectations, forecasting a full-year adjusted sales decline of 4% to 12%, narrowing from previous expectations. The market's upward revision of GLP-1 therapy demand has boosted investor confidence. On May 6, Novo Nordisk's obesity treatment drug sales performed well, growing by 22% at constant exchange rates, with strong demand for Wegovy driving the company's stock price up. The GLP-1 market is expanding, though pricing pressure remains. Eli Lilly down 0.09%, with increased trading volume. Based on recent key news: On May 6, Eli Lilly announced an additional investment of $4.5 billion in its Indiana manufacturing facility to support the production of the newly approved oral weight loss drug Foundayo. This investment plan shows the company's focus on the weight loss drug market, which may drive stock price volatility. On May 5, Barclays raised Eli Lilly's target stock price from $135 to $140, reflecting the market's optimistic expectations for the company's future performance, which may positively impact the stock price. On May 6, Eli Lilly initiated an investment-grade bond issuance to raise funds to support recent acquisition transactions. This move demonstrates the company's proactive attitude towards business expansion, which may influence stock price trends. The pharmaceutical industry is active in mergers and acquisitions, with noticeable capital inflow. Johnson & Johnson down 1.08%, with increased trading volume. Based on recent key news: On May 5, Johnson & Johnson announced that its TREMFYA achieved positive results in a Phase 3 study for treating Crohn's disease. The study reached its primary endpoint at week 24, showing significant clinical improvement; however, the stock price still fell by 1.32%. Source: RTTNews On May 5, Johnson & Johnson's combination antibody therapy JNJ-4804 showed potential in treating refractory inflammatory bowel disease. Despite this positive news, the stock price remains under pressure. Source: JNJ Stock News On May 5, market analysts rated Johnson & Johnson as a moderate buy but did not include it in the top recommended stocks list, which may have affected investor confidence. Source: MarketBeat The pharmaceutical industry has shown stable performance recently, with limited capital inflow Stocks Ranked Among the Top by Market Capitalization AstraZeneca rose by 1.67%. Based on recent news, On May 4th, AstraZeneca announced significant progress in its collaboration project with Chengyi Biological, which is expected to have a positive impact on future revenues. This news boosted market confidence and drove the stock price up. On May 4th, Bernstein analyst Justin Smith maintained a buy rating on AstraZeneca and set a target price of £186. The analyst's positive assessment further enhanced investor confidence, pushing the stock price higher. On May 6th, MarketBeat reported that although AstraZeneca currently has a moderate buy rating among analysts, some top analysts believe there are better investment options available. This news had a minimal impact on the stock price, but it still warrants attention. The pharmaceutical industry has performed strongly recently, and investor sentiment is optimistic